Physician profile
William H Devlin
NPI 1871575860
$8,677.67
in general payments reported to CMS, 2019-2025
24 companies · $231 in 2025
The $231 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,184 · 2020: $925 · 2021: $712 · 2022: $5,066 · 2023: $230 · 2024: $330 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $790.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $5,418.78 | 2019-2022 | |
| Abiomed | $523.45 | 2019-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $355.74 | 2019-2023 | |
| Boston Scientific Corporation | $348.27 | 2019-2025 | Watchman Flx |
| Astrazeneca Pharmaceuticals Lp | $261.85 | 2019-2020 | |
| Amgen INC. | $237.58 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $214.28 | 2019-2025 | Lifevest |
| Amarin Pharma, INC. | $187.29 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $166.75 | 2019-2020 | |
| Abbott Laboratories | $151.23 | 2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| E.R. Squibb & Sons, L.L.C. | $135.79 | 2019-2023 | Camzyos |
| Corindus INC. | $119.18 | 2019 | |
| Edwards Lifesciences Corporation | $115.99 | 2020-2025 | Sapien 3 Ultra Resilia |
| Ablative Solutions, INC. | $86.98 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.37 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $49.76 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $45.97 | 2019-2022 | |
| Esperion Therapeutics, INC. | $42.89 | 2021 | |
| Chiesi USA, INC. | $38.10 | 2022-2023 | Kengreal |
| Philips North America LLC | $36.83 | 2021 | |
| Alnylam Pharmaceuticals INC. | $28.46 | 2021 | |
| Kestra Medical Technology Services, INC. | $20.01 | 2024 | Assure Wcd |
| Merck Sharp & Dohme LLC | $19.30 | 2021 | |
| Preventice Services, LLC | $11.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Devlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.